Kernal Biologics Raises $25M Series A Financing
Summary
Kernal Biologics, Inc., a Cambridge, Mass.-based development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life, closed a $25m Series A financing. In connection with the financing, Firat Ileri, Managing Partner of Hummingbird Ventures joins the board. The company intends to use the funds to extend its mRNA 2.0 platform and support the filing of an IND for immuno-oncology candidate KR-335. and Co-founder and President Burak Yilmaz, M.S., Kernal Biologics leverages mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease — while eliminating as many common side effects as possible. The proprietary mRNA technology is engineered to move in stealth, undetected by the immune system, and encrypted to home in on cancer cells, making it distinctively onco-selective.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kernal Biologics Raises $25M Series A Financing in the interactive ISVWorld profile.